Barinthus Biotherapeutics plc
Support and Resistance Levels
Past performance
News About BRNS
All events for BRNS
All deals for BRNS
Financial Ratios
Financial Statements
BRNS vs Sector & Peers
About Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses. Website barinthusbio.com
Headquarters Germantown, MD, US